Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrolment for a phase 2b clinical trial of BPS-804 (Setrusumab) intended for the treatment of osteogenesis imperfect (OI), it was reported yesterday.
The product has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency for the product for OI, a form of brittle bone disease.
The investigational OI drug has also been accepted into the European Medicines Agency's Adaptive Pathways Program and was offered PRIority MEdicines (PRIME) designation.
The trial is a multi-centre, randomised, double-blind, dose-finding phase 2b study named ASTEROID and will assess the drug in a total of 112 adult patients across the United States and Europe, according to the company.
BeOne Medicines' sonrotoclax receives FDA Breakthrough Therapy Designation for MCL
Ascletis selects once-monthly SQ GLP-1R/GIPR dual peptide agonist, ASC35, for clinical development
Celltrion's biosimilar EYDENZELT (aflibercept-boav) approved by US FDA
Rigel Pharmaceuticals begins dose expansion phase of R289 study in lower-risk MDS
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Oxford Biomedica expands US operations with acquisition of viral vector facility in North Carolina
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Ananda Pharma achieves key Phase 1 milestone for MRX1 CBD program
Alvotech and Advanz Pharma announce EMA acceptance of AVT23 marketing application
Polarean expands Ascend Imaging partnership to boost US market reach